Literature DB >> 24315309

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer.

Hua Wang1, Zhijian Cai2, Fei Yang2, Juan Luo3, Makoto Satoh4, Yoichi Arai5, Dechuan Li6.   

Abstract

OBJECTIVE: To evaluate the therapeutic efficacy of AxdAdB-3 with Arg-Gly-Asp (RGD)-fiber modification (AxdAdB3-F/RGD), which enables integrin-dependent infection in bladder cancers.
METHODS: Flow cytometric analysis was applied to evaluated adenovirus-mediated gene transduction into various cells. The cytopathic effects of AxdAdB3-F/RGD were evaluated in bladder cancer cell lines and a normal bladder mucosa-derived cell line (HCV29) with AxCAZ3-F/RGD (control) or AxdAdB-3. The efficacy of bladder instillation therapy with AxdAdB3-F/RGD for orthotopic bladder cancer was investigated in nude mice.
RESULTS: Expression of coxsackievirus adenovirus receptor (CAR) and integrins (αvβ3 and αvβ5) vary in different bladder cancer cell lines. The susceptibility of various cell lines to adenovirus was associated with the expression of CAR. AxdAdB-3 was more cytopathic in CAR-positive bladder cancer cells than in CAR-negative cells, whereas AxdAdB3-F/RGD caused effective oncolysis in both CAR-positive and CAR-negative bladder cancer cells. AxdAdB3-F/RGD was not cytotoxic to HCV29 cells. Direct instillation of AxdAdB3-F/RGD into the bladder of the orthotopic model, established by CAR-deficient human bladder cancer cells, inhibited tumor growth and led to significantly elongated survival.
CONCLUSION: E1A and E1B double-restricted oncolytic adenovirus with RGD fiber modification has enhanced infectivity and oncolytic effects to CAR-deficient bladder cancers, suggesting the therapeutic potential of AxdAdB3-F/RGD for bladder cancers.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24315309     DOI: 10.1016/j.urology.2013.10.025

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer.

Authors:  C-S Lu; J-L Hsieh; C-Y Lin; H-W Tsai; B-H Su; G-S Shieh; Y-C Su; C-H Lee; M-Y Chang; C-L Wu; A-L Shiau
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

Review 2.  Targeted therapies in bladder cancer: an overview of in vivo research.

Authors:  Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

3.  RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.

Authors:  Y Yang; H Xu; J Shen; Y Yang; S Wu; J Xiao; Y Xu; X-Y Liu; L Chu
Journal:  Cell Death Dis       Date:  2015-05-14       Impact factor: 8.469

4.  A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.

Authors:  Wenjuan Cao; Junqiang Tian; Chong Li; Yanjun Gao; Xingchen Liu; Jianzhong Lu; Yuhan Wang; Zhiping Wang; Robert S Svatek; Ronald Rodriguez
Journal:  Virol J       Date:  2017-08-08       Impact factor: 4.099

Review 5.  Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer.

Authors:  Dmitriy Smolensky; Kusum Rathore; Maria Cekanova
Journal:  Drug Des Devel Ther       Date:  2016-10-05       Impact factor: 4.162

6.  Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.

Authors:  Selas T F Bots; Vera Kemp; Steve J Cramer; Diana J M van den Wollenberg; Marten Hornsveld; Martine L M Lamfers; Gabri van der Pluijm; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2022-03       Impact factor: 5.695

7.  Quantitative Analysis of Differential Proteome Expression in Bladder Cancer vs. Normal Bladder Cells Using SILAC Method.

Authors:  Ganglong Yang; Zhipeng Xu; Wei Lu; Xiang Li; Chengwen Sun; Jia Guo; Peng Xue; Feng Guan
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.